Latest updates to the ESMO bone health guidelines

Prof Robert Coleman - University of Sheffield, Sheffield, UK
Latest updates to the ESMO bone health guidelines ( Prof Robert Coleman - University of Sheffield, Sheffield, UK )
22 Sep 2020

Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort

Professor Jean-Yves Blay and Professor Florence Duffaud
Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort ( Professor Jean-Yves Blay and Professor Florence Duffaud )
14 Nov 2019

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld -  Erasmus MC Cancer Institute, Rotterdam, Netherlands )
25 Sep 2019

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA
Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )
25 Sep 2019

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients

Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK )
25 Sep 2019

HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
25 Sep 2019

Iberdomide in combination with dexamethasone for multiple myeloma

Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA
Iberdomide in combination with dexamethasone for multiple myeloma ( Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA )
25 Sep 2019